Delcath Systems (DV3R) Stock Overview
An interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
DV3R passed our risk checks.
DV3R Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Delcath Systems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.34 |
| 52 Week High | US$14.90 |
| 52 Week Low | US$7.20 |
| Beta | 0.53 |
| 1 Month Change | 4.10% |
| 3 Month Change | 25.40% |
| 1 Year Change | -36.45% |
| 3 Year Change | 36.38% |
| 5 Year Change | 4.38% |
| Change since IPO | -38.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| DV3R | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -4.2% | 2.0% | 1.6% |
| 1Y | -36.4% | -27.1% | 2.2% |
Return vs Industry: DV3R underperformed the German Medical Equipment industry which returned -27.1% over the past year.
Return vs Market: DV3R underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| DV3R volatility | |
|---|---|
| DV3R Average Weekly Movement | 5.2% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: DV3R has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: DV3R's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 156 | Gerard Michel | www.delcath.com |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma.
Delcath Systems, Inc. Fundamentals Summary
| DV3R fundamental statistics | |
|---|---|
| Market cap | €323.90m |
| Earnings (TTM) | €482.46k |
| Revenue (TTM) | €77.78m |
Is DV3R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DV3R income statement (TTM) | |
|---|---|
| Revenue | US$90.44m |
| Cost of Revenue | US$12.69m |
| Gross Profit | US$77.75m |
| Other Expenses | US$77.19m |
| Earnings | US$561.00k |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.016 |
| Gross Margin | 85.97% |
| Net Profit Margin | 0.62% |
| Debt/Equity Ratio | 0% |
How did DV3R perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/28 07:38 |
| End of Day Share Price | 2026/05/27 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Delcath Systems, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Gorman | BTIG |
| Marie Thibault | BTIG |
| John Newman | Canaccord Genuity |